Lv71
3690 积分 2023-08-11 加入
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist
1个月前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial
1个月前
已完结
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
1个月前
已完结
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer
1个月前
已完结
Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial
1个月前
已完结
Discovery ofHighly Efficacious CRBN-Based KRAS DegradersTargeting Cancers with KRAS G12D and G12V Mutations
1个月前
已完结
Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study
1个月前
已完结
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
1个月前
已完结
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study
2个月前
已完结
Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations
2个月前
已完结
皖公网安备34019202002308
